RITA Medical to Present at the Thomas Weisel Partners Healthcare Conference 2006
September 06 2006 - 6:46PM
PR Newswire (US)
FREMONT, Calif., Sept. 6 /PRNewswire-FirstCall/ -- RITA Medical
Systems, Inc. (NASDAQ:RITA), a publicly-traded medical device
company focused solely on cancer therapies, today announced that it
will present at the Thomas Weisel Partners Healthcare Conference,
which will take place at the Four Seasons Hotel in Boston. The
presentation, which is scheduled for 9:45 AM Eastern Time on
Friday, September 8, 2006, will include a review of the Company's
business strategy and historical financial results. Attendance at
the conference is by invitation only. RITA Medical will offer a
live audio webcast of its presentation which may be accessed at the
Company's website at http://www.ritamedical.com/. An archived
replay of the presentation will also be available approximately
three hours following the live presentation and will also be
available at http://www.ritamedical.com/. About RITA Medical
Systems, Inc. RITA Medical Systems develops, manufactures and
markets innovative products for cancer patients including
radiofrequency ablation (RFA) systems and embolization products for
treating cancerous tumors as well as percutaneous vascular and
spinal access systems. The Company's oncology product lines include
implantable ports, some of which feature its proprietary Vortex(R)
technology; tunneled central venous catheters; and safety infusion
sets and peripherally inserted central catheters used primarily in
cancer treatment protocols. The radiofrequency product line also
includes the HABIB 4X resection device, which coagulates a
"surgical resection plane" and is designed to facilitate a fast
dissection in order to minimize blood loss and blood transfusion
during surgery. The proprietary RITA RFA system uses radiofrequency
energy to heat tissue to a high enough temperature to ablate it or
cause cell death. In March 2000, RITA became the first RFA company
to receive specific FDA clearance for unresectable liver lesions in
addition to its previous general FDA clearance for the ablation of
soft tissue. In October 2002, RITA again became the first company
to receive specific FDA clearance, this time for the palliation of
pain associated with metastatic lesions involving bone. The Company
also distributes LC Bead embolic microspheres in the United States.
The LC Bead microspheres are injected into selected vessels to
block the blood flow feeding a tumor, causing it to shrink over
time, and are often used in combination with radiofrequency
ablation (RFA). The RITA Medical Systems website is at
http://www.ritamedical.com/. DATASOURCE: RITA Medical Systems, Inc.
CONTACT: investors, Doug Sherk, , or Jennifer Beugelmans, both at
+1-415-896-6820, or media, Steve DiMattia, +1-646-277-8706, or ,
all for RITA Medical Systems, Inc.; or Joseph DeVivo, President and
CEO of RITA Medical Systems, Inc., +1-510-771-0400 Web site:
http://www.ritamedical.com/
Copyright
Rita Medical (NASDAQ:RITA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Rita Medical (NASDAQ:RITA)
Historical Stock Chart
From Aug 2023 to Aug 2024